Likewise, the anti-NKG2A-mAb-IgG4 targets inhibitory NKG2A receptors on NK cells and disrupts their interaction with HLA-E (nonclassical MHC-I), strengthening NK-mediated anti-tumor responses24,25. Here, KLRC1 is linked to neoplasm.